Research that is free to access for all investors. Companies commission these providers to write research about them.
Brokers who write research on their corporate clients and make it available through our main bundle offering.
Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.
Event in Progress:
Research Tree provides access to ongoing research coverage, media content and regulatory news on Well SA. We currently have 0 research reports from 0 professional analysts.
Trinity Delta view: Prioritisation of the Therapeutics division continues, with Christina Coughlin’s appointment as CEO (having been on the Board since March 2022 and Head of R&D since February 2024). Once the Diagnostics division has been divested, Avacta will become a fully focused biotech company. This strategy is underpinned by the proprietary pre|CISION platform, and lead peptide drug conjugate AVA6000. Completion of the two-weekly safety study and progression into dose expansion cohorts du
Companies: Avacta Group PLC
Trinity Delta
Avacta reported results for FY23 but more importantly announced the appointment of Christina Coughlin as CEO wef 1 May, replacing Alastair Smith who is stepping down today. FY23 results were better than consensus at the EPS level. Net cash ended the year at £16.6m, as previously disclosed, which has since been bolstered by the £31m gross equity raise enabling Avacta to fund the AVA6000 programme through Phase 2 clinical trials, as well as advancing other candidates in its pre|CISION™ and Affime
Capital Access Group
This morning's FY results from ANX suggest that substantial growth opportunities remain in its three businesses in the credit hire and legal services areas, with these as ever serving high-demand markets. ANX is the UK market-leader in credit hire and legal services for impecunious no-fault motorists, while also operating Housing Disrepair and Vehicle Emissions litigation businesses. Last year, Credit Hire saw judicious management of the fleet during the period in order to make the best use of a
Companies: Anexo Group Plc
WHIreland
Companies: Deltic Energy Plc
Canaccord Genuity
Companies: Christie Group plc
Shore Capital
Following on from the news, earlier in the year, of a conspicuous, £10m, contract win, this morning's FY23A results demonstrate rapid growth for the business last year, with revenues +27% YoY. 2023 was a year of investment for CODE, with a series of meaningful upgrades to the learning, marketing and administrative platforms leaving the business well-placed to develop profitably, as projected in our forecasts. Gross margin remained robustly above 60% and the company saw double digit increases bot
Companies: Northcoders Group PLC
1st May 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: REDX Pharma (REDX.L) has delisted from the AIM Market What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing
Companies: TXP CNC RNO MAI ANX IUG CUSN POLB
Hybridan
Hostelworld’s pioneering and fast-evolving ‘social’ strategy is delivering aplenty. Material outperformance of the hostel market (FY23 bed nights sold up 30% vs industry 8%) and low-cost acquisition and retention of high-value customers (over a million social members after just 18 months) confirm the success of the company’s app-centric model, which taps into the social media habits of its target demographic to mutual benefit. With reducing marketing percentage of revenue on track to meet the FY
Companies: Hostelworld Group Plc
Edison
Please find below our weekly update covering themes that we feel that are of interest to investors and participants in the small and mid-cap TMT sector as well as commentary on recent newsflow.
Companies: SKL ENET CHSS
Allenby Capital
Post further analysis of the FY 2023 results on 9 April 2024, we are establishing FY 2025 forecasts, as well as modifying our forecast adjusted net profit/EPS figures for 2024 and 2025 to reflect the accounting of the deferred tax asset. Our 2025 forecast calls for 9% growth in customer revenues, stable other operating income (largely R&D tax credits) vs 2024, EBITDA margins going back to the 23% level (after a slight contraction in 2024 to reflect 3 facilities being run in parallel for part of
Companies: hVIVO plc
Cavendish
Elixirr offers investors exposure to the long-term growth trends in the global Consulting market (including digitisation and the ongoing technology revolution, demand for innovation, efficiency and specialised expertise) all turbo charged by the group’s ‘challenger’ strategy driving market share gain from a low base. FY 2023 results showed the power of Elixirr’s differentiated model with revenue up +20% and adj. EPS up +22% in a market subdued by global uncertainty. With net cash of £18m, a posi
Companies: Elixirr International Plc
We are reiterating our Buy rating and $22.50 price target for Betterware after the company reported an impressive 1Q, with better than expected top line results. Further, management reiterated 2024 revenue and EBITDA guidance. There was also material progress at Betterware, which enjoyed double-digit increases in average ticket and revenue and is nearing the shift to positive growth in Associates. JAFRA Mexico also registered another strong quarter, as the acquisition has remained a key winner.
Companies: NUS MED NUS BWMX MED DDMX
Small Cap Consumer Research LLC
Full year results were in line with our revised expectations with strong revenue growth being driven by significant progress within the Bioplastics division but tempered by a reduction in sales within the RF Technologies division. The current year is expected to see a further increase in revenues, this time being delivered principally by a recovery in RF and a more modest increase in Bioplastic sales. We expect the Company to trade on a cash neutral basis and hence see gross cash levels remainin
Companies: Biome Technologies PLC
What you need to know: • Following a long period of consolidation, gold broke out in March, hitting record highs, and continuing to push higher as we enter April. • Silver and copper also had strong months up 10% and 4%, respectively. • More notably, we are finally seeing the equities outperform their underlying metal price with the GDX, SIL, and COPX up 22.7%, 21.1% and 19.4%, respectively, significantly outperforming broader markets. • With precious metals taking the limelight, the rest of the
Companies: FCX FCX OMG DPM OLA PRB LVG TM OGC CNRI ASCU
Atrium Research
The clinical diagnosis of Alzheimer’s Disease (AD) continues to be a highly challenging endeavour and existing gold standard diagnostic techniques (PET scans, CSF analysis) are limited by their cost, lack of access and perceived invasiveness. As the therapeutic landscape of AD evolves so too are the tools being developed to diagnose and monitor AD in clinical practice and blood-based AD tests represent potentially more sustainable, scalable and economically viable approaches to future AD managem
Companies: Bioventix Plc
Share: